Counterfeit Alli investigation leads to two arrests
A joint enforcement operation in the US has led to the arrests of two people accused of being involved in supplying counterfeit weight loss medication, including GSK’s Alli (orlistat).
The US Food and Drug Administration (FDA) was involved in the operation which investigated the sale of weight loss products found to contain undeclared active pharmaceutical ingredients (API). These APIs include sibutramine, a substance that can cause seizures, heart attack or stroke.
“International borders and the perceived anonymity of the Internet will not deter FDA from investigating violations of the law”, added Margaret Hamburg, Commissioner of Food and Drugs.
